High effectiveness of recommended first-line antiretroviral therapies in Germany: a nationwide, prospective cohort study
- PDF / 769,577 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 95 Downloads / 161 Views
ORIGINAL PAPER
High effectiveness of recommended first‑line antiretroviral therapies in Germany: a nationwide, prospective cohort study Markus Bickel1 · Christian Hoffmann2,3 · Eva Wolf4 · Axel Baumgarten5,6 · Christoph Wyen7,8 · Christoph D. Spinner9 · Hans Jäger10 · Nils Postel11 · Stefan Esser12 · Markus Mueller13 · Albrecht Stoehr14 · Stefan Preis15 · Stephan Klauke1,6 · Knud Schewe2,6 · for the PROPHET study group of dagnae e.V. Received: 8 February 2020 / Accepted: 13 April 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Purpose Current German/Austrian antiretroviral treatment guidelines recommend more than 20 combination regimens for first-line therapy, without a preference. Regimens include two nucleoside reverse transcriptase inhibitors (NRTIs) plus either an integrase strand transfer inhibitor (INSTI), a non-NRTI (NNRTI) or a boosted protease inhibitor (PI). The objective was to examine the outcomes of recommended first-line ART in Germany. Methods This nationwide observational study included treatment-naïve chronically HIV-1 infected patients receiving one of the recommended first-line regimens. Patients were allocated to three arms (INSTI, NNRTI, PI) and were prospectively followed for 24 months. Delayed treatment initiation was defined by a baseline CD4 T-cell count of
Data Loading...
